PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16275144-5	2006	MG132 treatment resulted in stabilization of EGFR tyrosine phosphorylation and its association with c-Cbl.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	Cbl proto-oncogene	Homo sapiens	100-105	
10531381-7	1999	MG132, a proteasome inhibitor, significantly prolonged the ligand-induced phosphorylation of both the EGFR and c-Cbl.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	Cbl proto-oncogene	Homo sapiens	111-116	
19764654-11	2009	Treatment of cells with proteasomal inhibition MG132 blocked the loss of Cbl only partially.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	47-52	Cbl proto-oncogene	Homo sapiens	73-76	
25084697-3	2014	We found that Src was degraded mainly by the proteasomal pathway because the proteasome inhibitor MG-132 but not the lysosome inhibitor NH4Cl suppressed the EPO-induced degradation of Src in F-36P cells and that knockdown of Cbl inhibited EPO-induced ubiquitination and degradation of Src in F-36P cells.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	98-104	Cbl proto-oncogene	Homo sapiens	225-228